KCNJ16 and thyroid cancer: This study may provide greater insights into the dedifferentiation features associated with TSHR expression in thyroid cancer and Kir5.1, which may be a potential therapeutic target in redifferentiation strategies for recurrent and metastatic thyroid cancer, thus enabling the adoption of RAI therapy and other treatments.